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Meningococcal serogroup C (MenC) vaccination of men 
who have sex with men (MSM) was temporarily recom-
mended to control an outbreak of invasive MenC dis-
ease among MSM in Berlin in 2012–2013. Vaccination 
was offered to HIV-infected MSM free of charge; others 
had to request reimbursement or pay out of pocket. We 
aimed to assess (i) awareness and acceptance of this 
recommendation through an online survey of MSM, 
(ii) implementation through a survey of primary care 
physicians and analysis of vaccine prescriptions, and 
(iii) impact through analysis of notified cases. Among 
online survey respondents, 60% were aware of the rec-
ommendation. Of these, 39% had obtained vaccination 
(70% of HIV-infected, 13% of HIV-negative/non-tested 
MSM). Awareness of recommendation and vaccina-
tion were positively associated with HIV infection, 
primary care physicians’ awareness of respondents’ 
sexual orientation, and exposure to multiple informa-
tion sources. Most (26/30) physicians informed clients 
about the recommendation. Physicians considered 
concerns regarding reimbursement, vaccine safety 
and lack of perceived disease risk as primary barriers. 
After the recommendation, no further outbreak-related 
cases occurred. To reach and motivate target groups, 
communication of a new outbreak-related vaccination 
recommendation should address potential concerns 
through as many information channels as possible and 
direct reimbursement of costs should be enabled.
Introduction
Neisseria meningitidis (Nm) is a gram-negative diplo-
coccus that commonly colonises the human pharynx 
and respiratory tract [1]. Nm can sometimes cause 
invasive meningococcal disease (IMD), presenting as 
meningitis and/or sepsis. Thus far, 13 serogroups have 
been identified; of these A, B, C, W, X and Y cause vir-
tually all IMD [2]. Similar to other European and North 
American countries [3], serogroup B, followed by C, 
predominate in Germany, with IMD incidence showing a 
decreasing trend, from 0.95 cases/100,000 inhabitants 
in 2001 to 0.45/100,000 in 2011 [4]. Overall case fatal-
ity from 2009 to 2011 was 7.8%, significantly higher for 
meningococcal C (MenC) (10.9%) than for meningococ-
cal B (MenB) disease (7.6%). Incidence was highest in 
infants (8.1 cases/100,000 inhabitants) and toddlers 
(4.8), with a second, smaller peak in 15-19 year-old 
adolescents (2.0) [4].
The overall prevalence of nasopharyngeal meningococ-
cal carriage is about 10%, but varies markedly in dif-
ferent age and population groups [5-8]. Very high Nm 
carriage rates of over 40% have been reported in men 
who have sex with men (MSM) [9-10], and one study 
reported higher carriage rates in MSM (23.8%) than in 
heterosexual men (11.6%) [11]. Further known risk fac-
tors for meningococcal disease, such as exposure to 
tobacco smoke and crowding [12, 13], may also be more 
prevalent in venues where MSM meet. Since 2001, IMD 
clusters in MSM have been reported in Toronto (2001) 
[14], Chicago (2003) [15] and New York City (2010–2013) 
[16-17]. All outbreaks were caused by MenC and were 
of the multilocus sequence type (MLST) 11 (ST-11) [18]. 
The outbreaks in Toronto and Chicago (six cases each) 
ended rapidly after carrying out targeted MenC vac-
cination campaigns in the gay communities affected. 
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However, the New York outbreak (22 cases) was more 
protracted despite intensive efforts to vaccinate MSM.
From October 2012 to May 2013, five IMD cases in MSM 
living in Berlin were notified to local health authorities 
(LHA). The patients were between 22 and 28 years old; 
none were HIV-positive. All cases were caused by MenC 
strains belonging to ST-11 of the fine type PorA(P)1.5-
1,10-8:FetA(F)3-6 [19]. In addition, four of the five 
strains from these patients had fHbp allele 766, that 
had not been described previously. All five cases pre-
sented with severe sepsis; four died. Only two of the 
cases had a definite epidemiological link, having spent 
a night together shortly before illness onset [19]. In 
this time period MenC clusters among MSM were also 
reported from New York, Los Angeles and Paris and a 
single case from Belgium. All European strains showed 
similar characteristics [20].
It has been estimated that 80,000 MSM (95%CI 
74,000–104,000) aged 20–59 years live in Berlin [21-
22]. Among these, an estimated 10,800 MSM had 
been diagnosed with HIV as of the end of 2013 [22]. 
Assuming the age distribution among MSM is similar 
to that of men in the general population, an estimated 
18,000 MSM aged 20–29 years live in Berlin, among 
whom four MenC IMD cases occurred in the first half 
of 2013. The resulting incidence of 11 cases/100,000 
inhabitants [23] was markedly higher than the nation-
wide incidence of 0.7/100,000 in 20–29 year old men 
in 2012 [24].
Prevention of IMD with meningococcal conjugate vac-
cines is highly effective [25]. In Germany, MenC vacci-
nation was recommended for all one year-old children 
in 2006; older children can obtain the vaccine on an 
individual basis free-of-charge. Vaccination cover-
age of adolescents increased gradually, reaching 59% 
among 15-17 year-olds in 2013 based on statutory 
health insurance (SHI) claims data (Thorsten Rieck, 
personal communication, January 2015). In addition, 
vaccination against serogroups ACWY (MenACWY) is 
recommended for persons with congenital or acquired 
immunodeficiencies with residual T- and/or B-cell func-
tion, especially complement/properdin deficiencies, 
hypogammaglobulinaemia, and asplenia. While HIV 
infection is not explicitly listed, it is considered to be 
an indication for meningoccal vaccination under this 
rubric. Quadrivalent meningococcal vaccination is also 
recommended for travellers to endemic areas. Finally, 
vaccination is recommended to control regional IMD 
outbreaks when three or more cases of an identical 
Figure 1
Number of men who have sex with men reached by various information sources and vaccination status after meningococcal 
serogroup C vaccination recommendation, Berlin, November 2013–January 2014
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serogroup occur in a specific age group in a particu-
lar region within three months in conjunction with an 
attack rate of 10 or more cases per 100,000 inhabitants 
in the respective population [26].
Thus, in response to this outbreak, the competent 
authorities of the federal state of Berlin recommended 
meningococcal vaccination for all MSM with a vaccine 
licensed for adults to protect against serogroup C as of 
27 July 2013, following advice from the Berlin Advisory 
Board for Immunisation and announced in a press 
release on 18 July 2013 [27]. Female partners of MSM 
were not targeted in this recommendation. The rec-
ommendation was to remain in effect until 31 January 
2014, but was subsequently extended to 31 December 
2014, pending an evaluation of its impact. The recom-
mendation did not entail reimbursement of the vaccine 
by SHI. However, most insurance companies adopted 
a policy of individual evaluation and reimbursement 
upon request. The gay community and physicians were 
informed via internet forums as well as by radio, TV and 
the print media. The recommendation was promoted in 
counselling centres of the gay and lesbian community 
in Berlin, by the German and Berlin AIDS service organ-
isations (DAH and BAH, respectively), the AIDS working 
group of practicing physicians in Berlin (AK AIDS), the 
German association of practising physicians treating 
Figure 2
Number of prescribed doses of quadrivalent meningococcal serogroups ACWY conjugate vaccines according to quarter and 
federal state, Germany, 1 January 2012–30 June 2014
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HIV-infected patients (DAGNÄ) and via regional and 
national gay Internet portals.
Our goal was to evaluate the awareness and imple-
mentation of the temporary MenC vaccination recom-
mendation for MSM in Berlin by surveying MSM and 
physicians. In addition, we analysed IMD cases notified 
in Berlin after implementation of the recommendation, 
including the molecular epidemiology of MenC cases, 
to confirm that the outbreak had been interrupted.
Methods
Internet-based survey among men who have sex 
with men
Starting in the late 1980s, anonymous knowledge, 
attitude and behaviour (KAB) surveys on HIV/AIDS 
were conducted every two to four years among MSM in 
Germany [28]; from 2007 onwards these were carried 
out online exclusively. Questions on the Berlin vacci-
nation recommendation were included in the nation-
wide survey made available online from November 
2013 until mid-January 2014. Participants living in 
Berlin were asked how they obtained information on 
the MenC vaccination campaign and whether they 
obtained vaccination. They were recruited by personal-
ised instant messages and banners on social network-
ing and dating websites for MSM. Two multivariable 
logistic regression models were constructed to ana-
lyse factors potentially associated with awareness of 
the recommendation and with MenC vaccine uptake, 
respectively. The following factors were investigated: 
demographic and behavioural characteristics such 
as age, educational status, income, reported sexual 
orientation, openness regarding sexual orientation 
towards colleagues and their physician, affinity to gay 
subculture (visiting gay venues), information seeking 
pertaining to HIV, HIV testing, and HIV status, number 
of sexual partners in the previous year, and sources 
used to obtain information on the Berlin vaccination 
recommendation. Respondents who reported MenC 
vaccination before the recommendation was issued 
were excluded from this analysis.
The online survey protocol was evaluated and approved 
by the ethical review board of the Charité University 
Clinic in Berlin (EA1/266/13).
Prescription of meningococcal conjugate 
vaccines
The number of monovalent MenC or quadrivalent 
MenACWY conjugate vaccine doses prescribed within 
SHI from July 2013 to March 2014 was analysed based 
on data from Insight Health (http.//insight-health.
de/). This database contains data from pharmaceuti-
cal data-processing centres on all directly reimbursed 
prescriptions for > 99% of persons insured by SHI (85% 
of the population) in Germany. However, data on recipi-
ents’ age and sex are not available. SHI reimburses 
all prescriptions for vaccinations recommended by the 
German Standing Committee for Vaccination (STIKO). 
Thus, prescriptions for meningococcal vaccination of 
people living with HIV (PLWHIV) were included in the 
Insight Health database, since vaccination was already 
recommended by STIKO for this group before the out-
break. However, meningococcal vaccination for non-
HIV-infected, otherwise-healthy MSM living in Berlin 
as recommended by the Berlin authorities was not 
covered directly by SHI and thus not registered in this 
database. Rather, patients had to fill individual private 
prescriptions that SHI reimbursed on a voluntary basis.
Survey of primary care physicians
In February 2014 we conducted a cross-sectional sur-
vey among privately practicing physicians belong-
ing to AK AIDS, who represent almost all primary HIV 
care providers and are known as MSM-friendly. We 
assumed that most MSM would seek vaccination from 
one of these practices, which covered a range of rel-
evant medical specialties. The study was presented in 
January 2014 at the AK AIDS working group meeting to 
motivate members to participate. Since most members 
worked in group practices, we conducted the survey 
per practice. We used a written anonymous question-
naire eliciting participants’ demographics (age, sex, 
physician specialty, location and type of practice), the 
number of MSM clients and HIV-infected patients in 
the practice population, information channels used to 
inform patients, vaccination practices in general and 
MenC vaccination practices in particular, including 
type of vaccine used, possible obstacles to immunisa-
tion and vaccine uptake by MSM. After pre-testing, the 
questionnaire was distributed on 14 January 2014 to all 
45 practices, with a total of about 70 practicing phy-
sicians. Returned questionnaires were entered elec-
tronically using Microsoft Excel 2010. We conducted a 
descriptive analysis, including calculation of propor-
tions and 95% confidence intervals (CI).
Figure 3
Vaccination coverage for meningococcal serogroups C and 
ACWY vaccination as estimated by physicians at the time 
of the survey in participating practices for men who have 
sex with men without HIV-infection and HIV-infected 
patients
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Surveillance of invasive meningococcal disease 
cases in men who have sex with men after 
meningococcal C vaccine recommendation
In Germany, surveillance of IMD is based on statutory 
notification by physicians and laboratories to LHAs 
[29]. LHAs transmit laboratory-confirmed and epidemi-
ologically linked IMD cases to the Robert Koch Institute 
(RKI) via the federal state authorities according to a 
standardised case definition. These data are routinely 
matched to data of invasive meningococcal strains that 
undergo molecular genetic typing at the national ref-
erence laboratory for meningococci and Haemophilus 
influenzae (NRLMHi) as described previously [30]. 
During the outbreak, all LHA in Berlin were requested 
to elicit sexual orientation of IMD cases in men which 
is otherwise not routinely done. Ethical approval was 
not necessary since according to the Protection against 
Infection Act, local health authorities are authorised to 
request information on any risk factors relevant to out-
break control in patients and forward this information 
anonymously to the Robert Koch Institute. Possible 
outbreak-related cases were defined as follows: All 
MenC IMD in MSM aged 20-49 years, living in Berlin 
with illness onset from 1 July 2013 to 31 August 2014.
Results
Internet-based survey among men who have sex 
with men
MenC-related questions were answered by 1,471 online 
survey participants. Of these, 42 (2.9%) reported MenC 
vaccination before the recommendation was published 
and were excluded from further analysis, leaving a 
study sample of 1,429 men.
The median age of respondents was 40 years (range: 
16–78 years); 72% had at least a high school diploma. 
The majority (78%) reported exclusively male sexual 
partners in the previous 12 months, but only 37% 
reported regularly visiting gay venues. About half 
(52%) stated that they were single, 44% reported hav-
ing a steady male partner, and 4% a steady female part-
ner. Most (81.5%) had been tested for HIV at least once; 
among those tested (n = 1,199), 23% were HIV-positive. 
Table 1 presents demographic, behavioural and infor-
mation-seeking characteristics stratified according to 
awareness of the recommendation and vaccine uptake.
Of all participants, 852 (59.6%) were aware of the 
recommendation and 333 (23.3%) obtained MenC 
vaccination. Positive HIV status, the primary health-
care provider being aware of the respondent’s sexual 
orientation, having received information about the 
recommendation from a larger number of different 
information channels, higher educational level, and 
>  10 sexual partners in the past year were indepen-
dently associated with both awareness of the rec-
ommendation and obtaining vaccination (Table 2). 
Frequent visits to gay venues were also significantly 
associated with awareness, while men who reported 
having mainly female partners were less likely to have 
heard of the recommendation (Table 2). Over two-thirds 
(69.6% (183/263) of HIV-infected MSM, but only 12.9% 
(150/1,166) of non-tested or HIV-negative participants 
reported obtaining MenC vaccination.
MSM whose physicians personally recommended 
MenC vaccination during a healthcare visit had the 
highest vaccine uptake, followed by those who learned 
of the recommendation through HIV/AIDS informa-
tion and support organisations. However, only 18.8% 
(268/1,429) of all survey participants and 31.5% of 
survey participants aware of the vaccination recom-
mendation (268/852) were exposed to these sources. 
The highest number of MSM was reached through MSM 
online and print media, followed by general print and 
broadcast media, but vaccine uptake among these 
MSM was lower (Figure 1).
Prescription of meningococcal conjugate 
vaccines
From Q1 2012 to Q2 2014, the number of monova-
lent conjugate MenC vaccine doses (Menjugate Kit, 
NeisVac-C and Meningitec) prescribed and directly 
reimbursed by SHI fluctuated between 159,000 and 
213,000, with peak values in Q3 2012 as well as Q3 
2013 in all federal states and the lowest number in 
Q1 2013. In contrast, the number of prescribed and 
directly reimbursed doses of quadrivalent conjugate 
ACWY vaccines (Nimenrix and Menveo) increased 
markedly in Q3 of 2013 (Figure 2). By far the largest 
increase (ca 37-fold, from a mean of 159 doses per 
quarter in Q1 2012 to Q2 2013 to 6,001 in Q3 2013) was 
seen in Berlin, but increases were also seen in other 
states. Thereafter, the number of prescriptions for 
MenACWY vaccines decreased rapidly, but remained 
two- to three-fold higher in most federal states than 
prior to Q3 2013. In Berlin, 7,798 doses of quadrivalent 
vaccine were prescribed in Q3 2013 to Q2 2014, com-
pared with 635 expected doses based on the mean of 
159 per quarter in Q1 2012 to Q2 2013. If we assume 
the 7,163 excess doses were mainly used to vaccinate 
MSM known to be HIV-positive, this implies up to 66% 
of the estimated 10,800 MSM with HIV diagnoses living 
in Berlin received meningococcal vaccination.
Survey of primary care physicians
Of 45 distributed questionnaires, 30 (66.7%) were 
returned completed. The respondents’ median age was 
50 years (range: 41–64 years), 22 were male and six 
female. The two most common disciplines of the sur-
veyed practices were family (n=12) and internal medi-
cine (n=13), followed by dermatology (n=4). This was 
similar to the distribution of disciplines among all con-
tacted practices. Of responding physicians, 22 worked 
in group practices and eight in solo practices. Practice 
size was highly variable, and thus also the number of 
patients with an existing or new indication for MenC 
vaccination. Based on the participants’ estimates, an 
average of 480 HIV-infected patients (median: 425; 
range 1–2,000) and 530 MSM without HIV-infection 
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(median: 200; range 1-3,000) attended each practice 
annually.
As summarised in table 3, surveyed physicians learned 
of the vaccination recommendation most frequently 
through the Berlin Senate press release (n=30) or 
HIV-specific medical networks (n=14). Of the 30 prac-
tices, 26 actively informed their patients about the 
new MenC vaccination recommendation, usually dur-
ing routine consultations. Before the recommendation 
was issued, 20 practices regularly vaccinated certain 
patient groups against MenC. International travel was 
the most common indication (19/20), with only 5/20 
reporting HIV-related immunodeficiency as being an 
indication.
Responding physicians estimated MenC vaccine uptake 
to be markedly higher among HIV-infected patients 
than HIV-non-infected patients in February 2014, ca 6 
months after implementation of the recommendation 
(Figure 3). They administered quadrivalent MenACWY 
vaccine almost exclusively (28/29) rather than a mon-
ovalent vaccine. Twenty-two practices reported that 
MSM patients sometimes declined MenC vaccination 
despite the recommendation, most commonly due to 
a lack of perceived risk, a negative attitude towards 
vaccination, or fear of side effects (Table 3). Half the 
responding physicians believed that concerns regard-
ing reimbursement of vaccination costs by SHI led to 
refusal of the recommended vaccination in approxi-
mately onethird of eligible patients in these practices.
Table 1
Demographic and behavioural characteristics of Internet survey respondents resident in Berlin stratified according to 
awareness of vaccine recommendation and vaccine uptake, November 2013–January 2014 (n=1,429)
Unaware of 
campaign  
n=577
Aware, not 
vaccinated  
n=519
Aware, 
vaccinated  
n=333
Row 
totals 
N = 
1,429
Pearson’s 
chi-squared 
test
n % n % n %
Age group (years old)
<25 89 15.4% 68 13.1% 14 4.2% 171
<0.001
≥25 488 84.6% 451 86.9% 319 95.8% 1,258
Education
<High school diploma 176 31.2% 131 25.5% 84 25.7% 391
0.075
≥High school diploma 389 68.8% 382 74.5% 243 74.3% 1,014
Monthly income
<€1,000 125 23.2% 89 18.2% 56 17.7% 270
0.062
≥€1,000 413 76.8% 401 81.8% 260 82.3% 1,074
Openness regarding 
sexual orientation towards 
co-workers
≥50% know 275 50.3% 369 73.8% 252 79.5% 896
<0.001
<50% know 272 49.7% 131 26.2% 65 20.5% 468
Openness regarding 
sexual orientation towards 
primary care provider
Is informed 211 36.6% 285 54.9% 294 88.3% 790
<0.001
Does not know/unsure 366 63.4% 234 45.1% 39 11.7% 639
Visiting gay venues
Infrequent 435 75.5% 212 34,2% 153 45.9% 894
<0.001
Frequent 141 24.5% 306 59.1% 180 54.1% 533
Sexual orientation
Exclusively male sex partners 401 69.5% 424 81.7% 291 87.4% 1,116
<0.001Predominantly male sex partners 101 17.5% 77 14.8% 41 12.3% 219
Predominantly female sex partners 75 13.0% 18 3.5% 1 0.3% 94
HIV test status
HIV-positive 38 6.7% 42 8.1% 183 55.0% 263
<0.001
HIV-negative 
recent test ≤12 months 216 37.4% 229 44.1% 112 33.6% 557
HIV negative 
test >12 months ago 152 26.3% 157 30.3% 29 8.7% 338
Never tested 171 29.6% 91 17.5% 9 2.7% 271
Number of information 
sources on MenC 
recommendation
None, unaware of vaccination 
recommendation 577 100.0% 0 0.0% 0 0.0%
a 577
<0,0011–2 NA NA 342 66.3% 187 56.3% 529
3–4 NA NA 141 27.3% 99 29.8% 240
≥5 NA NA 33 6.4% 46 13.9% 79
Number of sexual partners 
in previous 12 months
≤1 159 27.9% 102 19.8% 32 9.7% 293
<0.001
2–5 221 38.8% 159 30.8% 64 19.3% 444
6–10 85 14.9% 96 18.6% 56 16.9% 237
>10 105 18.4% 159 30.8% 179 54.1% 443
MenC: meningococcal C; NA: not applicable.
a Men already vaccinated before the vaccination recommendation targeting men who have sex with men were excluded from this analysis
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Invasive meningococcal disease cases in men 
who have sex with men after meningococcal C 
vaccine recommendation
No further outbreak-related cases occurred in Berlin 
from July 2013 to August 2014. Only four men with 
MenC IMD were notified in Berlin from July 2013 to 
August 2014, aged 37–48 years. None were MSM. 
While strains from two of these cases had the fine type 
P1.5-1,10-8:F3-6, the other two did not. None had fHbp 
allele 766. MenC incidence in 20–29-year old men in 
Berlin decreased from 1.58 cases/100,000 inhabit-
ants in the first half of 2013 (four cases) to none in the 
second half of 2013, and none in the first half of 2014. 
From 2008 to 2012, annual MenC incidence in this age 
group in Berlin ranged from 0 to 0.79 (1–2 cases/year). 
The outbreak strain with fHbp 766 was not identified in 
any female cases.
Discussion
We evaluated the implementation, acceptance and 
impact of a temporary MenC vaccination recommen-
dation issued in response to a MenC outbreak among 
MSM in Berlin in 2013. In the 13 months following 
endorsement of the recommendation, no further out-
break-related cases were reported among MSM. As LHA 
elicited sexual orientation of all reported IMD cases, it 
is unlikely that cases in MSM were missed. The recom-
mendation led to enhanced meningococcal vaccination 
activities among MSM, but primarily among those with 
an HIV diagnosis. It seems plausible that the targeted 
vaccination campaign reduced meningococcal trans-
mission in the population at risk. However, due to the 
rare and sporadic nature of IMD occurrence, it is pos-
sible that the outbreak would have also ended without 
enhanced vaccination activities.
Table 2
Results of two multivariable logistic regression models analysing factors associated with awareness of the vaccination 
recommendation and uptake of the MenC vaccine, Berlin, November 2013–January 2014
Factors 
Awareness of vaccination campaign (n=1,346) Vaccine uptake (n=786) 
Number of 
individuals OR 95% CI p
Number of 
individuals OR 95% CI p
Primary care physician 
Unaware of patient’s sexual preference(s) 766 Ref. NA NA 542 Ref. NA NA
Aware of patient’s sexual preference(s) 580 2.1 1.6-2.8 <0.000 244 2.6 1.7–4.2 <0.000 
HIV status 
HIV-positive 257 Ref. NA NA 209 Ref. NA NA
HIV-negative ≤12 months 532 0.4 0.3-0.6 <0.000 316 0.1 0.1–0.2 <0.000 
HIV-negative >12 months 315 0.4 0.3-0.7 <0.000 172 0.1 0.03–0.1 <0.000 
Never tested for HIV (status unknown) 242 0.3 0.2-0.4 <0.000 89 0.1 0.02–0.1 <0.000 
Number of partners within past 12 months 
2–5 partners 410 Ref. NA NA 202 Ref. NA NA
≤1 partner 278 0.8 0.6–1.2 0.294 129 0.5 0.3–1.0 0.044 
6–10 partners 229 1.3 0.9–1.8 0.226 138 1.0 0.6–1.7 0.978
>10 partners 429 1.8 1.3–2.5 0.001 317 1.6 1.0–2.5 0.057 
Number of information sources on the vaccination campaign 
1–2 sources NA NA NA NA 482 Ref. NA NA
3–4 sources NA NA NA NA 226 1.3 0.9–1.9 0.214
≥5 sources NA NA NA NA 78 2.5 1.4–4.5 0.003 
Level of education 
≤Secondary school 376 Ref. NA NA 199 Ref. NA NA
≥High-school diploma 970 1.6 1.2–2.1 0.001 587 1.7 1.1–2.7 0.012 
MSM venues: infrequent or no visits 
Infrequent or no visits 837 Ref. NA NA 421 NS NS NS
Regular visits 509 1.7 1.3–2.2 <0.000 365 NS NS NS
Sexual partner(s) 
Male only 1,057 Ref. NA NA 665 NS NS NS
Majority male 201 0.8 0.6–1.1 0.138 104 NS NS NS
Majority female or female only 88 0.3 0.2–0.5 <0.000 17 NS NS NS
NA: not applicable; NS: not significant; OR: odds ratio; 95%CI: 95% confidence interval; Ref: reference group.
Factors excluded from the model as non-significant: income (≤ EUR1,000 /month vs > EUR 1,000/month); age (≤25 years-old vs >25 years-old).
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As IMD clusters in the MSM community seem to be a 
recurring problem [14-16,18], heightened awareness 
should be upheld during routine surveillance to ensure 
early detection of and response to outbreaks in this 
group. All IMD cases should be reported promptly to 
responsible LHA and sexual orientation elicited during 
epidemiological case investigation.
The results of the surveys among MSM and physicians 
and vaccine prescription data showed both directly 
and indirectly that targeting information to the rel-
evant groups was effective, reaching an estimated 
60% of MSM according to the internet-based survey. 
Preventive measures such as pneumococcal and influ-
enza vaccination were well established in the eve-
ryday practice of physician members of the working 
group on AIDS, likely facilitating the prompt response 
to the new recommendation. Almost all responding 
practices reported offering the recommended MenC 
vaccine during patient visits. The conditions for the 
Table 3
Survey results of physicians of the working group on AIDS regarding the temporary implementation of meningococcal 
serogroup C vaccine recommendation for men who have sex with men in Berlin Berlin, Germany, February 2014 (n=30)
Question n % 95% CI
How did you learn of the MenC vaccination recommendation for MSM in Berlin? (n=30) 
Press release by the Senate of Berlin 20 66.7 50.2–83.8
German association of practising physicians treating HIV-infected patients (DAGNÄ) 14 46.7 29.1–64.9
German AIDS service organisation (DAH) 10 33.3 16.2–49.8
Berlin AIDS service organisation (BAH) 9 30.0 13.6–46.4
From patients 6 20.0 7.9–38.1
Gay community counselling centres in Berlin 7 23.3 5.7–34.3
Gay community Internet portals 4 13.3 1.0–25.0
Have you informed your MSM patients of the temporary MenC vaccination recommendation? (n=30) 
Yes 26 86.7 75.0–99.9
No 4 23.3 1.0–25.0
If yes, how did you inform your patients? (n=26) 
During routine consultation 24 92.3 81.6–102.4
Information sheets and/or poster 7 26.9 9.9–44.1
Patient letter 3 11.5 -0.5–24.5
Did you regularly vaccinate certain groups of patients against meningococcal disease prior to the announcement of the recommendation? 
(n=29) 
Yes 20 69.0 52.2–85.8
No 9 31.0 14.2–47.8
What were the indications for vaccination against meningococcal disease?(n=20) 
Travel vaccination 19 95.0 95.4–104.6
HIV infection independent of a immunodeficiency 5 25.0 6.0–44.0
Immunodeficiency due to HIV infection 4 20.0 2.5–37.5
Routine childhood immunisation 3 15.0 -0.6–30.6
General immunisation of MSM 0 0.0 -
What vaccine did you use for the MenC vaccination? (n=29) 
Quadrivalent MenACWY conjugate vaccine 28 96.6 90.8–96.6
Monovalent MenC conjugate vaccine 1 3.4 -3.2–9.2
Did any patients decline the recommended MenC vaccination? (n=28) 
Yes 22 78.6 63.9–94.1
No 6 21.4 5.9–36.1
If yes, why? (n=22) 
Patient considered themselves to be not at risk 20 90.9 79.0–103.0
General refusal of vaccinations 17 77.3 59.4–94.6
Fear of side effects 16 72.7 54.4–91.6
Concerns that cost of vaccine would not be reimbursed 14 63.6 43.9–84.1
MenC disease not perceived as dangerous 8 36.4 15.9–56.1
Feared stigmatisation 4 18.2 1.9–34.1
Others advised against vaccination 4 18.2 1.9–34.1
Doubts about the effectiveness of the vaccine 3 13.6 -0.5–28.5
CI: confidence interval; MenC: meningococcal serogroup C; MSM: men who have sex with men.
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implementation of a new vaccination recommendation 
were particularly favourable in this network of compe-
tent and dedicated physicians with an interest in treat-
ment of HIV-infected patients. For MSM who did not 
routinely consult such practices, the situation might be 
different. Their doctors may not have offered meningo-
coccal vaccination due to a lower level of awareness 
of the recommendation. Nonetheless, estimated vac-
cination coverage according to participating physicians 
was similar to that based on analysis of prescription 
data and the online survey.
The majority of meningococcal vaccinations were 
administered to HIV-positive MSM, over two thirds of 
whom were vaccinated based on the internet survey 
and prescription data, versus only 13% of the HIV-
negative or untested internet survey participants. This 
may reflect less frequent physician contacts in the 
latter group. In addition, primary care providers also 
faced healthcare system- and patient-related barriers 
to vaccine delivery, including uncertainty regarding 
reimbursement of vaccination costs, fear of side effects 
and scepticism towards vaccination in general. Being 
required to at least indirectly reveal their sexual orien-
tation to SHI to receive reimbursement for MenC vac-
cination may have been a further barrier for patients. 
In future similar situations, it might be helpful to com-
municate more detailed information on vaccine safety 
and requirements for reimbursement during the initial 
promotion of the campaign. Convincing SHI companies 
to directly reimburse vaccination costs in the case of 
outbreak-related vaccination recommendations and/or 
to provide funding for anonymous and free community-
based vaccination sites would likely increase willing-
ness to receive vaccination in similar situations.
In agreement with other studies, our survey among 
MSM showed that personal advice from the physician 
is pivotal in influencing willingness to be vaccinated 
[31-32]. In this case of a vaccination recommendation 
being limited to MSM, the physicians’ recommenda-
tion had an even greater impact when the sexual ori-
entation of the patient was known, emphasising the 
importance of a trusting doctor-patient relationship. In 
addition, vaccination could be conveniently obtained at 
routine healthcare visits, at least in HIV-positive MSM. 
In the implementation of a preventive measure such 
as a vaccination campaign, it is a particular challenge 
to reach the population most at risk. Our results show 
that repeated information via different sources led to 
higher vaccination uptake, similar to the findings of 
Friedman et al. during a community-wide hepatitis A 
vaccination campaign [33]. Nonetheless, 40% of MSM 
who participated in the online survey were unaware of 
the campaign. These men tended to be less open about 
their sexual orientation, reported less risky sexual 
behavior and visited gay venues less often. It would 
still be important to reach this group for targeted pre-
vention measures, and for this, other channels of infor-
mation must be identified.
Despite the long-standing STIKO recommendation to 
vaccinate immunocompromised patients against IMD, 
the majority of HIV-positive online survey participants 
(96%) were not vaccinated prior to the Berlin MenC 
vaccination recommendation. Only 20% of physicians 
in the practice-based survey stated that HIV-related 
immunodeficiency was an indication for meningococcal 
vaccination prior to the recommendation. Rather, travel 
abroad was the most common indication for menin-
gococcal vaccination of MSM. The prescription data 
showed that MenC vaccine uptake increased in states 
other than Berlin as well. While this suggests that the 
Berlin MenC vaccination recommendation increased 
awareness for the pre-existing STIKO recommendation 
to immunise HIV-infected persons, more widespread 
education of physicians is required.
Our study has several limitations. Firstly, the impact 
of the vaccination campaign could only be determined 
indirectly through an observed decrease in the number 
of cases. Due to the sporadic nature of meningococ-
cal clusters, we cannot say definitively that no further 
cases would have occurred even without vaccination. 
Studies to investigate the direct impact of vaccination 
on circulation of the pathogen in the gay community 
would be extremely difficult to perform since coloni-
sation with MenC is very rare compared to other sero-
groups [5]. In addition, for population groups such as 
MSM it is impossible to determine the representative-
ness of an online sample. It is likely that MSM partici-
pants in the survey were more socially and sexually 
active, as well as more open about their sexual orien-
tation, than MSM who did not participate. Such MSM 
may be more easily reachable by a vaccination cam-
paign promoted through gay media [34-35]. However, 
the remarkable agreement in the estimated proportion 
of HIV-positive MSM vaccinated after the Berlin recom-
mendation based on the internet survey with prescrip-
tion data and physicians’ estimates suggests that at 
least HIV-positive MSM were well represented in the 
survey.
Conclusion
In conclusion, the vaccination campaign launched to 
control the IMD outbreak in Berlin achieved a marked 
increase in vaccination coverage in MSM with HIV. The 
much lower coverage achieved in non-tested or HIV-
negative MSM reflects known challenges of outbreak 
control in specific social groups such as MSM compared 
to in institutional settings [28]. Nonetheless, no further 
IMD cases occurred in MSM, and ongoing molecular 
genetic monitoring at the NRLMHi did not detect the 
outbreak strain in any IMD cases from Germany. A key 
finding of our study was that receiving information on 
the campaign from several sources increased vaccina-
tion uptake; thus widespread promotion of a new rec-
ommendation through all possible venues is crucial to 
reach target groups. Promotion of such a recommenda-
tion should also directly motivate persons in the tar-
get group to visit their physician and contact specific 
support groups, as these measures were associated 
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with the highest vaccine uptake. In particular, the 
long-standing and effective network of MSM-friendly 
physicians was crucial in implementing the vaccina-
tion campaign. Since lack of perceived risk for IMD 
and concerns regarding adverse vaccine effects were 
identified as important barriers to vaccination uptake, 
these issues should be more specifically addressed in 
future vaccination campaigns. Finally, in addition to 
direct reimbursement of physician-based vaccination, 
offering free and preferably anonymous vaccination 
at community-based vaccination sites might improve 
uptake, especially among those targeted persons who 
rarely consult a physician.
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